tetano
Editor, Senior Moderator
J Clin Microbiol. 2017 Dec 20. pii: JCM.01691-17. doi: 10.1128/JCM.01691-17. [Epub ahead of print]
[h=1]Parallel validation of three molecular devices for simultaneous detection and identification of influenza A, B and respiratory syncytial viruses.[/h] Ling L[SUP]1,[/SUP][SUP]2[/SUP], Kaplan SE[SUP]2[/SUP], Lopez JC[SUP]2[/SUP], Stiles J[SUP]2[/SUP], Lu X[SUP]1[/SUP], Tang YW[SUP]3,[/SUP][SUP]2[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Rapid identification of respiratory pathogens such as influenza viruses A (FluA), B (FluB) and respiratory syncytial virus (RSV) reduces unnecessary antimicrobial use and enhances infection control practice. We performed a comparative evaluation of three molecular methods; 1) ARIES Flu A/B & RSV, 2) Xpert Xpress Flu/RSV and 3) Cobas Flu A/B & RSV. The clinical performance of the three methods was evaluated using 200 remnant nasopharyngeal swab (NPS) specimens against a combined reference standard. The limits of detection (LODs) of the ARIES and the Xpert Xpress assays were determined using titer-known FluA, FluB, and RSV control strains. The 95% limits of detection were between 1.702 and 0.0003 TCID50 with no significant differences revealed among the three assays. Perfect qualitative detection agreement was obtained in the reproducibility study. The Cobas failed at the first run on 13 clinical specimens, resulting in an invalid rate of 6.5%. Sensitivities and specificities for all assays were 96.0-100.0% and 99.3-100% for all three viruses. For on-demand single-specimen and batched 12-specimen workflows, test turnaround time was 115.5 and 128.8 min for the ARIES (12 sample capacity), 34.2 and 44.2 min for the Xpress (16 sample capacity), and 21.0 and 254.4 min for the Cobas (one instrument), respectively. In summary, the ARIES, Xpress and Cobas Liat assays demonstrated excellent sensitivities and specificities for simultaneous detection and identification of FluA, FluB and RSV from NPS specimens in cancer patients. Test turnaround time was significantly shorter on the Xpress when instrument scalability is unlimited.
PMID: 29263204 DOI: 10.1128/JCM.01691-17
[h=1]Parallel validation of three molecular devices for simultaneous detection and identification of influenza A, B and respiratory syncytial viruses.[/h] Ling L[SUP]1,[/SUP][SUP]2[/SUP], Kaplan SE[SUP]2[/SUP], Lopez JC[SUP]2[/SUP], Stiles J[SUP]2[/SUP], Lu X[SUP]1[/SUP], Tang YW[SUP]3,[/SUP][SUP]2[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Rapid identification of respiratory pathogens such as influenza viruses A (FluA), B (FluB) and respiratory syncytial virus (RSV) reduces unnecessary antimicrobial use and enhances infection control practice. We performed a comparative evaluation of three molecular methods; 1) ARIES Flu A/B & RSV, 2) Xpert Xpress Flu/RSV and 3) Cobas Flu A/B & RSV. The clinical performance of the three methods was evaluated using 200 remnant nasopharyngeal swab (NPS) specimens against a combined reference standard. The limits of detection (LODs) of the ARIES and the Xpert Xpress assays were determined using titer-known FluA, FluB, and RSV control strains. The 95% limits of detection were between 1.702 and 0.0003 TCID50 with no significant differences revealed among the three assays. Perfect qualitative detection agreement was obtained in the reproducibility study. The Cobas failed at the first run on 13 clinical specimens, resulting in an invalid rate of 6.5%. Sensitivities and specificities for all assays were 96.0-100.0% and 99.3-100% for all three viruses. For on-demand single-specimen and batched 12-specimen workflows, test turnaround time was 115.5 and 128.8 min for the ARIES (12 sample capacity), 34.2 and 44.2 min for the Xpress (16 sample capacity), and 21.0 and 254.4 min for the Cobas (one instrument), respectively. In summary, the ARIES, Xpress and Cobas Liat assays demonstrated excellent sensitivities and specificities for simultaneous detection and identification of FluA, FluB and RSV from NPS specimens in cancer patients. Test turnaround time was significantly shorter on the Xpress when instrument scalability is unlimited.
PMID: 29263204 DOI: 10.1128/JCM.01691-17